IMTX vs TMO vs ILMN vs DHR

For growth investors, Immatics N.

V. (IMTX) is the stronger pick with 188. 6% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Illumina, Inc. (ILMN) offers the better valuation at 25. 5x trailing P/E (27. 2x forward), making it the more compelling value choice. Analysts rate Immatics N. V. (IMTX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Illumina, Inc.

(ILMN) is the cheapest at 25. 5x versus Immatics N. V. at 67. 7x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 18. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Illumina, Inc. wins at 6. 43x versus Danaher Corporation's 34. 35x.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +2. 8%, compared to -62. 8% for Illumina, Inc. (ILMN). Over 10 years, the gap is even starker: TMO returned +222. 6% versus ILMN's +3. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.

89β versus Immatics N. V. 's 1. 58β — meaning IMTX is approximately 77% more volatile than DHR relative to the S&P 500. On balance sheet safety, Immatics N. V. (IMTX) carries a lower debt/equity ratio of 3% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Immatics N.

V. (IMTX) is pulling ahead at 188. 6% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, IMTX leads at 64. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus 9. 8% for Immatics N. V. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DHR leads at 20. 9% versus -24. 8% for IMTX. At the gross margin level — before operating expenses — IMTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Illumina, Inc. (ILMN) is the more undervalued stock at a PEG of 6. 43x versus Danaher Corporation's 34. 35x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 18. 7x forward P/E versus 27. 2x for Illumina, Inc. — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IMTX: 88. 5% to $21. 00.

In this comparison, DHR (0.

7% yield), TMO (0. 4% yield) pay a dividend. IMTX, ILMN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

89), 0. 7% yield, +212. 4% 10Y return). Immatics N. V. (IMTX) carries a higher beta of 1. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHR: +212. 4%, IMTX: +18. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMTX is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock; ILMN is a mid-cap quality compounder stock; DHR is a mid-cap quality compounder stock. DHR pays a dividend while IMTX, TMO, ILMN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.